Fresh analysis suggests that patients who discontinue new weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end traditional diet and exercise programs.
Research printed in a leading health publication demonstrates that while obese individuals frequently drop substantial amounts of their body weight while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals buying these drugs need to be informed of the risk of fast weight regain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery means a reversion to pre-treatment mass in about a year and a half.
Comparing Therapies
The study, which examined dozens of trials involving thousands of patients, compared the effects of the injectable medications with other pills.
The team point out that individuals who lose weight through lifestyle changes alone usually experience a slower weight regain—around 100 grams monthly—after stopping.
Understanding the Quick Regain
Doctors propose the mechanism of the drugs accounts for the heightened rebound.
The injections imitate a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing the hormone levels far above than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this hormone supplement leads to hunger is no longer kept in check, making excessive eating a significant risk."
An Ongoing Issue?
Health authorities recommend the injections for people with obesity-related health risks, accompanied by recommended lifestyle changes.
Many experts say that, considering the high risk of weight regain, the therapy should be considered long-term.
This view is echoed by pharmaceutical companies, who state that the results "emphasize the chronic character of excess weight," comparing it to managing conditions like high blood pressure.
Patient Accounts
People who have stopped the medication describe a intense return of appetite.
"It was like a switch flipping and you become extremely hungry," recalled an individual.
The struggle is compounded if users have not developed sustainable dietary or behavioural changes during therapy.
Significant Interest
Survey data suggest that millions of adults in the UK have used these injections in the last 12 months, with desire continuing to grow.
- Adoption is more common among women compared to males.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
Finally, researchers stress that while these medications are potent agents for shedding pounds, they are not a magic fix and long-term success relies on ongoing lifestyle management.
